Moss-aGal (recombinant human alpha-galactosidase A) / Greenovation Biotech - LARVOL DELTA

Comparison of efficacy between subcutaneous and intravenous application of moss-aGal in the mouse model of Fabry disease. (PubMed, JIMD Rep) - "Here, we tested the efficacy of subcutaneous administration of moss-aGal and compared it with the results observed following iv infusion in Fabry mice. The obtained findings demonstrate that subcutaneously applied moss-aGal is correctly transported to target organs and efficacious in degrading Gb3 deposits there and thus suggest the possibility of using this route of administration for therapy of Fabry disease."

Journal • Preclinical • Fabry Disease • Genetic Disorders • Lysosomal Storage Diseases • Metabolic Disorders • Rare Diseases